Commerce Seeks Comments on Section 232 Lumber Investigation

This week, President Trump signed an executive order directing HHS to take steps to lower prescription drug prices, and the U.S. Department of Commerce announced an investigation into the impact of pharmaceuticals and pharmaceutical ingredients on U.S. national security.

Today, April 16, 2025, the Bureau of Industry and Security (BIS), a bureau within the U.S. Department of Commerce, published a “Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [...]

The post Commerce Seeks Comments on Section 232 Pharmaceutical Investigation first appeared on Alston & Bird's Washington Trade Watch blog.

The Biden Administration is increasing Section 301 tariffs on a wide range of Chinese imports for “strategic sectors.” Our International Trade & Regulatory Group examines the plan.

Both chambers are back in action this week, starting with finalizing committee assignments. The White House will welcome members, including a bipartisan luncheon for freshman members. The debt ceiling is in the back of everyone’s minds, but nothing official has been announced. The Senate will also take up more of President Biden’s nominations.

This week: The Trump-Xi meeting and the 100-day plan that should facilitate future economic discussions between the United States and China.